

A Quick Look at Using Pneumococcal Vaccines: PCV13 & PPSV23

Indications for Use

- Routine Schedule: **Pneumococcal Conjugate (PCV13)**
 - 4 doses: 2, 4, 6, 12-15 months
 - Minimum age 6 weeks
 - Routine use of PCV13 is **not** recommended for **healthy** children aged 5 years and older
- Routine Schedule: **Pneumococcal Polysaccharide (PPSV23)**
 - Single dose for adults aged 65 years and older
- Catch-up Schedule¹: **PCV13**
 - Healthy children who do not start or continue the series according to the routine schedule may need less doses to complete the series
 - Minimum Intervals
 - 4 weeks between doses given before age 12 months
 - 8 weeks between doses given at/after age 12 months
 - Age 65 years and older (**immunocompetent**) and no previous dose of PCV13
 - **May** administer 1 dose (shared clinical decision making)²

Risk-based Recommendations³: PCV13 & PPSV23

- Vary based on age, medical indication, and vaccination history

Vaccine Administration

- Administer **intramuscular (IM)** in the anterolateral thigh or deltoid of the arm⁴
- 1- to 1.5-inch needle; 22-25-gauge
- Use professional judgment when selecting needle length
- Can be given with other vaccines at the same visit
 - **Exceptions (see further points)**
 - PCV13 and PPSV23 should **not** be administered during the same visit
 - Those with HIV or asplenia: PCV13 and Menactra[®] should **not** be given at the same visit
 - Use separate sites, space at least 1-inch apart

Storage and Handling

- Store vaccines in the refrigerator at **36°F to 46°F (2°C to 8°C)**
- Do **not** freeze
- Pharmaceutical-grade (purpose-built) units are preferred for vaccine storage
- Keep in the original box with lid on
- Shake PCV13 vigorously before use

CONTRAINDICATIONS

- **PCV13**: Severe allergic reaction (e.g., anaphylaxis) after a previous dose of or to a component (including yeast) of PCV13 or any diphtheria-toxoid-containing vaccine
- **PPSV23**: Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component

PRECAUTIONS

- **PCV13 & PPSV23**: Moderate or severe acute illness with or without fever

FURTHER POINTS

- For persons with HIV or asplenia (functional or anatomic)
 - If using Menactra brand MenACWY vaccine, you should give PCV13 first with a 4-week interval between the final dose of PCV13 and Menactra
 - If using Menveo[®] brand MenACWY vaccine, give PCV13 at the same visit or at any interval before or after Menveo
- If **PCV13** was given before age 65 years, no additional PCV13 dose is needed regardless of risk factor
- If **PPSV23** is given at age 65 years or older, no additional PPSV23 dose is needed regardless of risk factor
- No more than 2 doses of PPSV23 are recommended before the 65th birthday and 1 PPSV23 dose thereafter
- Persons aged 65 years and older who received 1 or more doses of PPSV23 before age 65 years should receive 1 additional dose of PPSV23 that is at least 5 years after the previous PPSV23 dose
- Do not withhold vaccination in the absence of an immunization record or complete record
 - Vaccinate persons with uncertain or unknown vaccination status
- For persons recommended to receive both PCV13 and PPSV23, the 2 vaccines **should not** be administered at the same visit

- In circumstances where both PCV13 and PPSV23 are indicated regardless of age, doses of PCV13 should be administered first followed by PPSV23
 - Intervals between PCV13 and PPSV23 are based on age and risk factor (see table below)
 - Intervals may be different if PPSV23 is given first (see table below)
 - If either vaccine is inadvertently given earlier than the recommended interval, do not repeat the dose

Age Group	Underlying Conditions	Recommended Intervals	
		PCV13 to PPSV23	PPSV23 to PCV13
24-71 months	<ul style="list-style-type: none"> •Immunocompetent with underlying conditions •Functional or anatomic asplenia •Immunocompromised 	≥8 weeks	≥8 weeks
6-18 years	<ul style="list-style-type: none"> •High-risk immunocompetent (CSF leak, cochlear implant) •Functional or anatomic asplenia •Immunocompromised 	≥8 weeks	≥8 weeks
≥19 years	<ul style="list-style-type: none"> •High-risk immunocompetent (CSF leak, cochlear implant) •Functional or anatomic asplenia •Immunocompromised 	≥8 weeks	≥1 year
≥65 years	•All persons not in a risk group listed under ≥19 years (above)	≥1 year	≥1 year

***Recommended: when both are indicated, PCV13 should be given prior to PPSV23**

- The PCV13 and PPSV23 Vaccine Information Statement (VIS), including information about MCIR, can be found at www.michigan.gov/vis or your local health department
- Document as “PCV13 (Pevnar 13)” in MCIR, on the vaccine administration record, and on the immunization record card
- Document as “PPSV23 (Pneumovax)” in MCIR, on the vaccine administration record, and on the immunization record card

¹ Use CDC’s catch-up job aid, “Catch-Up Guidance for Healthy Children 4 Months through 4 Years of Age: PCV” at www.cdc.gov/vaccines/schedules/downloads/child/job-aids/pneumococcal.pdf

² For more detailed information regarding “shared clinical decision making” among adults aged 65 years and older, refer to “Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥ 65 Years: Updated Recommendations of the ACIP” (November 22, 2019) at www.cdc.gov/vaccines and CDC’s “ACIP Shared Clinical Decision Making Recommendations” at www.cdc.gov/vaccines/acip/acip-scdm-faqs.html

³ For guidance on immunizing children and adults at increased risk for pneumococcal disease, refer to “Pneumococcal Vaccination Recommendations for Children and Adults by Age and/or Risk Factor” at www.immunize.org/catg.d/p2019.pdf

⁴ PPSV23 may be given intramuscular (IM) or subcutaneous (Subcut); refer to “Administering Vaccines: Dose, Route, Site, and Needle Size” at www.immunize.org/catg.d/p3085.pdf

Publicly purchased PCV13 vaccine can be administered to eligible children aged 6 weeks through 18 years through the Vaccines for Children (VFC) program. Eligible children include those who are uninsured, underinsured, Medicaid eligible, Native American or Alaskan Natives. Contact your local health department for more information.

Through the Michigan Adult Vaccine Program (MI-AVP), adults 19 years and older can receive PCV13 and/or PPSV23 depending on age and risk factor. Eligible persons include those who are uninsured or underinsured and seen by an MI-AVP provider. For questions about MI-AVP, contact your local health department. For persons covered by Adult Medicaid, private stock should be used and billed to Medicaid.

For current PCV13 and PPSV23 recommendations visit www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html.